Zhitao Wei

Zhitao Wei

Auto-generated profile, based on publicly available information

Zhitao Wei

Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
GYGuanchao Ye
Guanchao Ye
ZWZhitao Wei
Zhitao Wei
CHChu Han
Chu Han
GWGuangyao Wu
Guangyao Wu
CWChinting Wong
Chinting Wong
ZSZhenwei Shi
Zhenwei Shi
Neoadjuvant chemoimmunotherapy (NACI) has significantly improved survival in patients with resectable non-small cell lung cancer (NSCLC). However, with the currently available methods (PD-L1, RECIST), it is difficult to predict who will benefit from treatment before therapy and who will achieve pathological complete response (pCR) before surgery. Non-invasive methods to predict treatment response to NACI could be used to further personalize treatment. In the multicenter retrospective study, we enrolled 534 patients with NSCLC who received NACI followed by surgical resection at three Chinese hospitals between January 2019 and December 2024 (193 patients from Center A, 193 patients from Center B, and 148 patients from Center C). We developed and validated Lung Cancer Neo-adjuvant Immuno-Chemotherapy Response Predictor (LC-NICER), a CT-based Artificial Intelligence (AI) system that integrates longitudinal radiomics (tumor texture), deep learning (microenvironmental context), and habitat imaging (tumor and peritumoral subregional dynamics) to predict pCR by analyzing tumor spatiotemporal heterogeneity. The LC-NICER system consists of two complementary predictive models: LC-NICERα, a pretreatment model that identifies patients likely to benefit from NACI to guide personalized therapy, and LC-NICERδ, a preoperative model that evaluates tumor regression and resection feasibility to inform surgical planning. This study is registered at ClinicalTrials.gov (NCT06285058). Among the 386 patients from Center A and B, 308 were randomly assigned to the training dataset and 78 to the internal validation dataset, following an 8:2 split ratio. The 148 patients from Center C formed an independent and external test dataset. LC-NICER prediction system demonstrated excellent performance with the area under the curves (AUCs) of 0.950 (0.927–0.970) in the training cohort, 0.889 (0.796–0.961) in the internal validation cohort, and 0.870 (0.803–0.927) in the external test cohort. The LC-NICERα achieved an accuracy of 0.722 (0.668–0.772) before therapy, while LC-NICERδ showed significantly improved accuracy of 0.831 (0.800–0.861) before surgery. Notably, LC-NICER outperformed current clinical standards, with absolute accuracy improvements of 10% over PD-L1 testing (0.622 [0.564–0.683], p = 0.002) and 18% over RECIST 1.1 criteria (0.651 [0.610–0.693], p = 0.008). For easy clinical utility and research reproducibility, we developed and openly published a software. As a non-invasive AI system for predicting NACI response in NSCLC, LC-NICER may offer future clinical personalized therapeutic strategies, accelerate adaptive clinical trials, and optimize treatment decisions, potentially reducing reliance on invasive procedures. This work was supported by the Noncommunicable Chronic Diseases- 10.13039/501100018537 National Science and Technology Major Project (2024ZD0531100, 2024ZD0531101), the 10.13039/501100001809 National Natural Science Foundation of China (82472062, 62102103, 82473298, 82202148, 82502479), the 10.13039/501100012166 National Key Research and Development Program of China (2023YFC2508603), the 10.13039/501100003453 Natural Science Foundation of Guangdong Province of China (2024A1515011672), Regional Innovation and Development Joint Fund of 10.13039/501100001809 National Natural Science Foundation of China (U22A20345), Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application (2022B1212010011).

9 August 2024 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
PXPeng Xu
Peng Xu
ZWZhitao Wei
Zhitao Wei
CLChuchu Li
Chuchu Li
JYJiaqi Yuan
Jiaqi Yuan
ZLZaiyi Liu
Zaiyi Liu
WLWenbin Liu
Wenbin Liu
Novel drug-target interaction (DTI) prediction is crucial in drug discovery and repositioning. Recently, graph neural network (GNN) has shown promising results in identifying DTI by using thresholds to construct heterogeneous graphs. However, an empirically selected threshold can lead to loss of valuable information, especially in sparse networks, a common scenario in DTI prediction. To make full use of insufficient information, we propose a DTI prediction model based on Dynamic Heterogeneous Graph (DT-DHG). And progressive learning is introduced to adjust the receptive fields of node. The experimental results show that our method significantly improves the performance of the original GNNs and is robust against the choices of backbones. Meanwhile, DT-DHG outperforms the state-of-the-art methods and effectively predicts novel DTIs. The source code is available at https://github.com/kissablemt/DT-DHG .

2 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYanting Liang
Yanting Liang
ZWZhitao Wei
Zhitao Wei
YDYi Dai
Yi Dai
XCXiaobo Chen
Xiaobo Chen
SDSiyao Du
Siyao Du
ZSZhenwei Shi
Zhenwei Shi
Breast cancer diagnosis using magnetic resonance imaging remains limited by high false-positive rates and substantial inter-reader variability, especially for lesions classified as Breast Imaging Reporting and Data System (BI-RADS) category 4, often leading to unnecessary biopsies. Here we show that the BI-RADS 4 Lesions Analysis System (BL4AS), an artificial intelligence system powered by foundation models and leveraging the rich spatiotemporal information of dynamic contrast-enhanced MRI, addresses these diagnostic challenges. Developed on a multicenter dataset of 2,803 lesions from 2,686 female patients, BL4AS demonstrates robust performance with areas under the curve of 0.892-0.930 and significantly outperforms radiologists in specificity (0.889 versus 0.491). BL4AS-assisted interpretation significantly improves diagnostic accuracy for both senior and junior radiologists, reducing inter-reader variability by 24.5% and decreasing false-positive rates by 27.3%. BL4AS further stratifies lesions into subcategories (4 A, 4B and 4 C) for refined risk assessment, offering a practical tool for precision breast cancer management.

6 January 2026 in Cancer Letters
Verified
Journal Article
Open access
YHYilong Huang
Yilong Huang
ZWZhitao Wei
Zhitao Wei
GYGuanchao Ye
Guanchao Ye
YCYanfen Cui
Yanfen Cui
CLChuanpu Li
Chuanpu Li
ZSZhenwei Shi
Zhenwei Shi
Tumor-intrinsic biomarkers alone insufficiently predict pathological complete response (pCR) to neoadjuvant immunochemotherapy (NICT) in non-small cell lung cancer (NSCLC). Artificial intelligence (AI)-based three-dimensional CT-derived body composition may provide complementary predictive value. We evaluated its association with pCR following NICT in NSCLC. This multicenter retrospective study of NSCLC patients treated with NICT in China between July 2019 and July 2024. Pre- and post-treatment CT scans were used for automated T1-T12 localization and volumetric body composition segmentation. Metrics included skeletal muscle, intermuscular, visceral, and subcutaneous adipose volume index (SAVI), and their percentage changes between scans. Among 657 patients (mean age, 61.3 years; 87.4 % men), pCR rates were 39.7 % (training), 38.4 % (internal validation), and 34.9 % (external validation). In multivariable analysis, high baseline skeletal muscle volume index (SMVI) was independently associated with pCR (OR = 2.22). During NICT, each 1 % relative increase in SMVI was associated with a 16 % higher likelihood of pCR (OR = 1.16), whereas every 10 % relative increase in SAVI improved pCR probability (OR = 1.56). A machine learning model integrating clinical variables, baseline SMVI, %ΔSMVI, and %ΔSAVI demonstrated significantly better discrimination than models using clinical variables alone (p < 0.05) in all cohorts. The performance was observed in the internal and external validation cohorts, with sensitivities of 62.1 % and 52.8 %, and specificities of 66.7 % and 74.7 %, respectively. AI-based CT-derived body composition quantification, particularly baseline SMVI and dynamic changes in SMVI and SAVI during NICT, are independently associated with pCR in NSCLC. Incorporating these modifiable biomarkers into predictive models improves performance beyond clinical variables alone.

27 November 2025 in Expert Systems with Applications
Verified
Journal Article
Closed access
YLYaoqi Liu
Yaoqi Liu
SDSiyao Du
Siyao Du
ZXZeyan Xu
Zeyan Xu
ZZZhen Zhang
Zhen Zhang
ZWZhitao Wei
Zhitao Wei
WLWenbin Liu
Wenbin Liu

13 December 2025 in Digital Signal Processing
Verified
Journal Article
Closed access
XLXiangbin Luo
Xiangbin Luo
ZWZhitao Wei
Zhitao Wei
YLYanting Liang
Yanting Liang
CWChinting Wong
Chinting Wong
ZXZeyan Xu
Zeyan Xu
YWYing Wang
Ying Wang